Jia Z.a· Zhou W.b· Liang J.c· Zhang G.a· Fu J.a· Sun X.d

Author affiliations

aDepartment of Thoracic Surgery, The first Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
bDepartment of Nuclear Medicine, Xi’an Gaoxin Hospital, Xi’an, China
cDepartment of Radiotherapy, Shaanxi Provincial Cancer Hospital, Xi’an, China
dDepartment of General Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: July 21, 2022
Accepted: October 15, 2022
Published online: January 16, 2023

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 7

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Introduction: MIR155HG has been found to play an important role in malignant tumors, but little research has been done on its association with esophageal cancer (ESCC). The aim of this study was to investigate the relationship between MIR155HG polymorphisms and ESCC susceptibility in the Chinese Han population. Methods: 511 ESCC patients and 487 healthy controls were selected for this study. All subjects were genotyped using the Agena MassARRAY platform. We assessed the association between seven single nucleotide polymorphisms (SNPs) of the MIR155HG and ESCC risk by genetic model analysis. The false discovery rate (FDR) test and Bonferroni correction were usually used to detect false positives for the results. Meanwhile, the interaction between SNPs was analyzed by multifactor dimensionality reduction software to predict the ESCC risk. Results: The C allele of rs4143370 and the A allele of rs34904192 in MIR155HG can increase the risk of ESCC (odds ratio (OR) = 1.33, p = 0.024; OR = 1.30, p = 0.013). Furthermore, rs4143370 and rs34904192 were associated with an increased risk of ESCC. Stratified analysis showed that MIR155HG SNPs (rs4143370 and rs34904192) significantly increased ESCC risk in males. MIR155HG SNPs (rs4143370, rs34904192, and rs928883) were also strongly associated with an increased risk of ESCC in people aged >64 years. In addition, haplotype analysis of the seven SNPs of the MIR155HG showed that the CC haplotype was associated with ESCC risk (OR = 1.34, p = 0.024). Conclusion: This study revealed that MIR155HG SNPs were associated with an increased risk of ESCC. The results provided clues for clarifying the role of MIR155HG in ESCC.

© 2023 S. Karger AG, Basel

References Arnal MJD, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–43. Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol. 2017;115(5):564–79. Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210–5. Matejcic M, Gunter MJ, Ferrari P. Alcohol metabolism and oesophageal cancer: a systematic review of the evidence. Carcinogenesis. 2017;38(9):859–72. Dong J, Thrift AP. Alcohol, smoking and risk of oesophago-gastric cancer. Best Pract Res Clin Gastroenterol. 2017;31(5):509–17. Jin Y, Yang T, Li D, Ding W. Effect of dietary cholesterol intake on the risk of esophageal cancer: a meta-analysis. J Int Med Res. 2019;47(9):4059–68. Wang Y, Qin X, Wu J, Qi B, Tao Y, Wang W, et al. Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis. PLoS One. 2014;9(9):e107598. Moghadam AR, Mehramiz M, Entezari M, Aboutalebi H, Kohansal F, Dadjoo P, et al. A genetic polymorphism in the CYP1B1 gene in patients with squamous cell carcinoma of the esophagus: an Iranian Mashhad cohort study recruited over 10 years. Pharmacogenomics. 2018;19(6):539–46. Liu J, Yang Y, Li H, Liu Y, Sun Y, Wu J, et al. IL1R2 polymorphisms are associated with increased risk of esophageal cancer. Curr Mol Med. 2020;20(5):379–87. Zang B, Chen C, Zhao JQ. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population. Aging. 2020;12(4):3771–90. Cao R, Tang W, Chen S. Association between BTLA polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population. J Clin Lab Anal. 2020;34(6):e23221. Yue C, Li M, Da C, Meng H, Lv S, Zhao X. Association between genetic variants and esophageal cancer risk. Oncotarget. 2017;8(29):47167–74. Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene. 2001;274(1–2):157–67. Wu X, Wang Y, Yu T, Nie E, Hu Q, Wu W, et al. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017;19(9):1195–205. Niu L, Lou F, Sun Y, Sun L, Cai X, Liu Z, et al. A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation. Sci Adv. 2020;6(21):eaaz2059. Haasch D, Chen YW, Reilly RM, Grace Chiou X, Koterski S, Smith ML, et al. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol. 2002;217(1–2):78–86. Peng L, Chen Z, Chen Y, Wang X, Tang N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med. 2019;8(17):7161–73. Thiele JA, Hosek P, Kralovcova E, Ostasov P, Liska V, Bruha J, et al. lncRNAs in non-malignant tissue have prognostic value in colorectal cancer. Int J Mol Sci. 2018;19(9):2672. Qin Y, Liu X, Pan L, Zhou R, Zhang X. Long noncoding RNA MIR155HG facilitates pancreatic cancer progression through negative regulation of miR-802. J Cell Biochem. 2019;120(10):17926–34. Sun Y, Chen P, Wu J, Xiong Z, Liu Y, Liu J, et al. Association of polymorphisms in LOC105377871 and CASC16 with breast cancer in the Northwest Chinese Han population. 2019:e3131. Yang W, Ma F, Wang L, He X, Zhang H, Zheng J, et al. The association analysis between CYP24A1 genetic polymorphisms and the risk of ischemic stroke in Chinese Han population. 2019:e01503. Jin T, Wang L, He X, Liu M, Bai M, Rong H, et al. Association between DIO2 polymorphism and the risk of Kashin-Beck disease in the Tibetan population. J Gene Med. 2019;21(10):e3123. Wang Y, Zhang Y, Sun Y, Wu J, Chang J, Xiong Z, et al. Association between ACYP2 polymorphisms and the risk of renal cell cancer. Mol Genet Genomic Med. 2019;7(11):e966. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 2000;320(7247):1468. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928–9. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5. Gola D, Mahachie John JM, van Steen K, König IR. A roadmap to multifactor dimensionality reduction methods. Brief Bioinform. 2016;17(2):293–308. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–7. Xing C, Sun SG, Yue ZQ, Bai F. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother. 2021;134:111158. Shen L, Li Y, Hu G, Huang Y, Song X, Yu S, et al. MIR155HG knockdown inhibited the progression of cervical cancer by binding SRSF1. Onco Targets Ther. 2020;13:12043–54. Wu H, He G, Han H, Xiong W, Song T, Chen H, et al. Analysis of MIR155HG variants and colorectal cancer susceptibility in Han Chinese population. Mol Genet Genomic Med. 2019;7(8):e778. Zou W, Li X, Li C, Liu D, Lv Y, Yang Y, et al. Analysis of the relationship between MIR155HG variants and gastric cancer susceptibility. BMC Gastroenterol. 2020;20(1):17. Article / Publication Details

First-Page Preview

Received: July 21, 2022
Accepted: October 15, 2022
Published online: January 16, 2023

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 7

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.